News for Betta Pharmaceuticals Co., Ltd. (300558.SZ)

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC

**media[552869]**

Merus reports promising results for lung cancer antibody MCLA-129

Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why I'm neutral on RVMD stock.

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial...

The prevalence of Nasopharyngeal Cancer is increasing globally due to environmental, pathogen-mediated, and genetic factors as well as lifestyle factors,...

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in...

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase...

The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past years. The growing number...

/PRNewswire/ -- The

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and...

Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ETUTRECHT, The Netherlands and CAMBRIDGE, Mass., March 14, 2023 -- Merus N.V. , a clinical-stage oncology company developing... | March 14, 2023

GuruFocus Article or News written by insider and the topic is about: